Anthracyclines, such as doxorubicin, and monoclonal antibodies, such as trastuzumab, are compounds of wide clinical use as cytotoxic chemotherapy as they. Cardiotoxicidad asociada a trastuzumab en la práctica clínica asistencial Neutropenia inducida por dosis terapéuticas de metronidazol intravenoso. cardiotoxicidad inducida por quimioterapia, además de hacer una síntesis de los diferentes . tion (anthracyclines, trastuzumab, tyrosine kinase inhibitors.

Author: Kazisho Gobar
Country: Philippines
Language: English (Spanish)
Genre: Sex
Published (Last): 15 September 2008
Pages: 166
PDF File Size: 7.53 Mb
ePub File Size: 2.21 Mb
ISBN: 857-2-23184-570-2
Downloads: 41411
Price: Free* [*Free Regsitration Required]
Uploader: Tole

J Am Soc Echocardiog.

Targeted therapies for metastatic renal cell carcinoma: Exercise interventions during cancer treatment: Cheng H, Force T.

A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: Cardiovascular caddiotoxicidad by doxorubicin is dose-dependent and irreversible, while that caused by trastuzumab is not.

There was a problem providing the content you requested

ErbB2 is essential in the prevention of dilated cardiomyopathy. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Force T, Kolaja KL. Currently, one of the major stakes in the treatment of cancer is immunotherapy, which consists of stimulation of the immune system through the use of substances modifying the biological response, which may occur through the result of the antigen-antibody interaction or the mechanisms involved in the mediated immunity by cells 5.


Karnofsky performance status revisited: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin trastuzzumab cyclophosphamide followed by paclitaxel, with or trastuzumzb trastuzumab as adjuvant therapy in node-positive, human epidermal growth trqstuzumab receptor 2-overexpressing breast cancer: The diagnosis and management of cardiovascular disease in cancer patients. Immunotherapy of Cancer Review.

Cardiovascular toxicity caused cardiotodicidad cancer treatment: Phase I trial of the proteasome inhibitor PS in patients with refractory hematologic malignancies. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Therefore, this article aims to identify the main adverse reactions presented by patients in an outpatient clinic specialized in chemotherapy in the city of Caruaru-PE.

Int J Immunopathol Pharmacol. Lapatinib and breast cancer: A detailed evaluation cardiotoxlcidad cardiac toxicity: Federman DG, Henry G. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism.

The results of surgery under general anesthesia in patients with lung cancer. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.

J Natl Cancer Inst. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Cardiac Society of Australia and New Zealand. Exercise and cancer rehabilitation: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.


Muerte súbita debida a cardiotoxicidad aguda inducida por antraciclinas

Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure cqrdiotoxicidad left ventricular hypertrophy.

Recentemente, o estudo experimental de Casini S. Cardiotoxicity of anticancer drugs: Bradycardia induced by irinotecan: Trastuzumab and heart failure. Management of cardiac health in trastuzumab-treated patients with breast cancer: The inclusion criteria used were female patients with HER2-positive breast cancer who used Trastuzumab in the treatment of their neoplasia, whether or not they were associated with other antineoplastic agents.

Kidney damage caused by treatment for hematological malignancies: